← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

LENSAR, Inc. (LNSR) 10-Year Financial Performance & Capital Metrics

LNSR • • Industrial / General
HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems
AboutLENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.Show more
  • Revenue $53M +26.9%
  • EBITDA -$7M +22.7%
  • Net Income -$31M -118.3%
  • EPS (Diluted) -2.73 -108.4%
  • Gross Margin 48.33% -3.5%
  • EBITDA Margin -12.59% +39.1%
  • Operating Margin -19.94% +31.3%
  • Net Margin -58.71% -72.1%
  • ROE -95.42% -195.8%
  • ROIC -47.24% -51.9%
  • Debt/Equity 0.14 +186.4%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 11.9%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 2/9
  • ✗Negative free cash flow
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y11.87%
3Y15.79%
TTM21.02%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-209.86%

EPS CAGR

10Y-
5Y-
3Y-
TTM-200.68%

ROCE

10Y Avg-35.5%
5Y Avg-30.31%
3Y Avg-27.64%
Latest-19.52%

Peer Comparison

Surgical Energy & Ablation Systems
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
BDMDBaird Medical Investment Holdings Limited45.91M1.252.5517.74%33.62%33%0.53
IVFINVO Fertility, Inc.12.29M0.81-0.03116.25%-417.01%-495.09%0.78
AEMDAethlon Medical, Inc.2.64M2.71-0.03-0.2%0.13
HYPDHyperion DeFi, Inc.27.38M3.35-0.0614.14%-73.86%-36.05%
NAOVNanoVibronix, Inc.1.59M1.46-0.1112.05%-133.04%-8.41%0.19
ALURAllurion Technologies Inc.23.21M1.89-0.16-39.94%-251.56%
RBOTVicarious Surgical Inc.18.48M2.86-0.27-380.42%0.30
TELATELA Bio, Inc.44.09M0.99-0.7418.56%-50.61%-25.05%1.51

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+24.39M30.53M26.38M34.46M35.36M42.16M53.49M
Revenue Growth %-0.25%-0.14%0.31%0.03%0.19%0.27%
Cost of Goods Sold+14.78M17.3M12.31M16.63M15.4M21.06M27.64M
COGS % of Revenue0.61%0.57%0.47%0.48%0.44%0.5%0.52%
Gross Profit+9.61M13.23M14.07M17.83M19.95M21.11M25.85M
Gross Margin %0.39%0.43%0.53%0.52%0.56%0.5%0.48%
Gross Profit Growth %-0.38%0.06%0.27%0.12%0.06%0.22%
Operating Expenses+18.93M25.94M32.58M37.48M40.13M33.34M36.52M
OpEx % of Revenue0.78%0.85%1.23%1.09%1.14%0.79%0.68%
Selling, General & Admin16.14M17.15M23.77M23.89M27.17M26.1M26.49M
SG&A % of Revenue0.66%0.56%0.9%0.69%0.77%0.62%0.5%
Research & Development2.78M7.57M7.55M12.36M11.81M6.14M5.33M
R&D % of Revenue0.11%0.25%0.29%0.36%0.33%0.15%0.1%
Other Operating Expenses01.23M1.26M1.24M1.15M1.1M4.7M
Operating Income+-9.32M-12.71M-18.5M-19.65M-20.18M-12.23M-10.66M
Operating Margin %-0.38%-0.42%-0.7%-0.57%-0.57%-0.29%-0.2%
Operating Income Growth %--0.36%-0.46%-0.06%-0.03%0.39%0.13%
EBITDA+-4.73M-8.85M-15.43M-16.89M-16.77M-8.71M-6.73M
EBITDA Margin %-0.19%-0.29%-0.58%-0.49%-0.47%-0.21%-0.13%
EBITDA Growth %--0.87%-0.74%-0.09%0.01%0.48%0.23%
D&A (Non-Cash Add-back)4.59M3.87M3.07M2.76M3.41M3.52M3.93M
EBIT-9.25M-12.66M-18.43M-19.65M-20.18M-12.23M-6.94M
Net Interest Income+0-2M-1.34M34K17K85K103K
Interest Income3.27M0034K17K85K103K
Interest Expense02M1.34M0000
Other Income/Expense-3.26M-1.94M-1.27M51K263K-2.15M-20.74M
Pretax Income+-12.57M-14.66M-19.77M-19.6M-19.91M-14.38M-31.4M
Pretax Margin %-0.52%-0.48%-0.75%-0.57%-0.56%-0.34%-0.59%
Income Tax+20K000000
Effective Tax Rate %1%1%1%1%1%1%1%
Net Income+-12.59M-14.66M-19.77M-19.6M-19.91M-14.38M-31.4M
Net Margin %-0.52%-0.48%-0.75%-0.57%-0.56%-0.34%-0.59%
Net Income Growth %--0.16%-0.35%0.01%-0.02%0.28%-1.18%
Net Income (Continuing)-12.59M-14.66M-19.77M-19.6M-19.91M-14.38M-31.4M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-11.77-1.57-1.81-2.10-1.96-1.31-2.73
EPS Growth %-0.87%-0.15%-0.16%0.07%0.33%-1.08%
EPS (Basic)-11.77-1.57-1.81-2.10-1.96-1.31-2.73
Diluted Shares Outstanding1.07M10.64M10.93M9.37M10.16M10.97M11.52M
Basic Shares Outstanding1.07M10.64M10.93M9.37M10.16M10.97M11.52M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+11.75M17.18M58.38M44.81M33.72M46.44M41.98M
Cash & Short-Term Investments3.34M4.62M40.6M31.64M14.67M24.06M22.45M
Cash Only3.34M4.62M40.6M31.64M14.67M20.62M16.26M
Short-Term Investments000003.44M6.19M
Accounts Receivable3.3M3.89M2.46M4.99M6.24M4.32M6.48M
Days Sales Outstanding49.4246.4633.9852.8364.4237.4344.21
Inventory4.06M8.06M13.47M6.49M11.74M15.69M11.43M
Days Inventory Outstanding100.33170.15399.58142.43278.2271.95150.9
Other Current Assets472K0001.06M2.37M1.62M
Total Non-Current Assets+17.14M17.35M20.73M21.65M22.13M23.14M24.32M
Property, Plant & Equipment3.62M2.15M4.42M7.45M6.88M10.28M664K
Fixed Asset Turnover6.74x14.19x5.98x4.63x5.14x4.10x80.56x
Goodwill0000000
Intangible Assets12.29M13.37M12.11M10.87M12.12M11.03M6.11M
Long-Term Investments753K000442K492K1.16M
Other Non-Current Assets476K1.84M4.21M3.34M3.13M1.34M16.38M
Total Assets+28.89M34.54M79.12M66.47M55.84M69.58M66.3M
Asset Turnover0.84x0.88x0.33x0.52x0.63x0.61x0.81x
Asset Growth %-0.2%1.29%-0.16%-0.16%0.25%-0.05%
Total Current Liabilities+7.66M7.83M8.47M8.71M11.42M11.63M15M
Accounts Payable1.41M1.58M2.48M2.69M5.42M4.01M6M
Days Payables Outstanding34.8833.2773.5859.14128.4869.4679.16
Short-Term Debt653K000000
Deferred Revenue (Current)871K777K923K904K768K1000K1000K
Other Current Liabilities1.98M4.67M2.97M3.38M3.52M4.01M5M
Current Ratio1.53x2.19x6.90x5.14x2.95x3.99x2.80x
Quick Ratio1.00x1.16x5.30x4.40x1.92x2.64x2.04x
Cash Conversion Cycle114.88183.33359.98136.13214.13239.93115.95
Total Non-Current Liabilities+41.69M57.26M3.44M2.87M2.44M10.78M32.65M
Long-Term Debt41.21M20.2M00000
Capital Lease Obligations0333K3.31M2.8M2.27M1.75M2.09M
Deferred Tax Liabilities0000000
Other Non-Current Liabilities479K36.73M129K69K167K9.03M30.56M
Total Liabilities49.35M65.09M11.91M11.59M13.86M22.41M47.65M
Total Debt+41.21M20.53M3.81M3.31M2.8M2.31M2.61M
Net Debt37.87M15.92M-36.79M-28.32M-11.87M-18.31M-13.65M
Debt / Equity--0.06x0.06x0.07x0.05x0.14x
Debt / EBITDA-------
Net Debt / EBITDA-------
Interest Coverage--6.35x-13.81x----
Total Equity+-20.46M-30.55M67.21M54.88M41.98M47.18M18.65M
Equity Growth %--0.49%3.2%-0.18%-0.23%0.12%-0.6%
Book Value per Share-19.13-2.876.155.854.134.301.62
Total Shareholders' Equity-20.46M-30.55M67.21M54.88M41.98M47.18M18.65M
Common Stock96K11K109K110K111K113K116K
Retained Earnings-23.53M-38.19M-57.99M-77.59M-97.51M-111.89M-143.29M
Treasury Stock0000000
Accumulated OCI-23.53M00004K6K
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-1.89M-12.59M-13.79M-8.97M-14.86M-9.66M-2.27M
Operating CF Margin %-0.08%-0.41%-0.52%-0.26%-0.42%-0.23%-0.04%
Operating CF Growth %--5.68%-0.1%0.35%-0.66%0.35%0.76%
Net Income-12.59M-14.66M-19.77M-19.6M-19.91M-14.38M-31.4M
Depreciation & Amortization4.59M3.87M2.56M2.76M3.41M3.52M3.93M
Stock-Based Compensation1.32M102K9.04M6.87M6.61M5.54M2.67M
Deferred Taxes0-78K57K527K000
Other Non-Cash Items9.15M537K505K517K618K3.45M25.58M
Working Capital Changes5.92M-2.36M-6.19M-42K-5.58M-7.78M-3.04M
Change in Receivables443K14K1.33M-2.65M-1.44M1.08M-2.1M
Change in Inventory-876K-4.77M-8.7M2.33M-6.89M-7.46M-4.9M
Change in Payables663K127K910K213K2.73M-1.42M1.96M
Cash from Investing+-3.89M-2.09M-326K-354K-115K-4.16M-2.16M
Capital Expenditures-3.25M-2.09M-366K-354K-115K-236K-156K
CapEx % of Revenue0.13%0.07%0.01%0.01%0%0.01%0%
Acquisitions-------
Investments-------
Other Investing-644K000000
Cash from Financing+6.96M15.95M50M361K-1.99M19.76M78K
Debt Issued (Net)-------
Equity Issued (Net)-------
Dividends Paid-198K-31K-1.86M0000
Share Repurchases-------
Other Financing-214K-1.07M00-2.4M5.88M20K
Net Change in Cash-------
Free Cash Flow+-5.13M-14.68M-14.16M-9.32M-14.97M-9.89M-2.43M
FCF Margin %-0.21%-0.48%-0.54%-0.27%-0.42%-0.23%-0.05%
FCF Growth %--1.86%0.04%0.34%-0.61%0.34%0.75%
FCF per Share-4.80-1.38-1.29-0.99-1.47-0.90-0.21
FCF Conversion (FCF/Net Income)0.15x0.86x0.70x0.46x0.75x0.67x0.07x
Interest Paid0000000
Taxes Paid00019K3K18K24K

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)---107.89%-32.11%-41.12%-32.26%-95.42%
Return on Invested Capital (ROIC)-40.15%-689.23%-175.84%-51.74%-53.41%-31.1%-47.24%
Gross Margin39.41%43.33%53.35%51.75%56.44%50.06%48.33%
Net Margin-51.64%-48.01%-74.95%-56.88%-56.32%-34.11%-58.71%
Debt / Equity--0.06x0.06x0.07x0.05x0.14x
Interest Coverage--6.35x-13.81x----
FCF Conversion0.15x0.86x0.70x0.46x0.75x0.67x0.07x
Revenue Growth-25.18%-13.58%30.62%2.61%19.25%26.87%

Revenue by Segment

20202021202220232024
Product19.83M26.25M25.96M31.64M41.06M
Product Growth-32.35%-1.09%21.90%29.78%
Service2.95M3.25M3.48M4.07M4.9M
Service Growth-10.07%7.30%16.91%20.23%

Revenue by Geography

20202021202220232024
UNITED STATES11.6M15M18.78M25.26M28.91M
UNITED STATES Growth-29.30%25.14%34.54%14.43%
Europe3.59M5.8M4.41M5.58M10.16M
Europe Growth-61.79%-24.05%26.67%81.86%
Asia Excluding South Korea4.19M3.85M3.58M3.84M5.49M
Asia Excluding South Korea Growth--8.06%-7.24%7.27%43.04%
KOREA, REPUBLIC OF3.08M4.38M2.18M257K848K
KOREA, REPUBLIC OF Growth-42.35%-50.23%-88.21%229.96%
Other Geographical Region319K449K502K776K563K
Other Geographical Region Growth-40.75%11.80%54.58%-27.45%

Frequently Asked Questions

Growth & Financials

LENSAR, Inc. (LNSR) reported $59.1M in revenue for fiscal year 2024. This represents a 143% increase from $24.4M in 2018.

LENSAR, Inc. (LNSR) grew revenue by 26.9% over the past year. This is strong growth.

LENSAR, Inc. (LNSR) reported a net loss of $51.5M for fiscal year 2024.

Dividend & Returns

LENSAR, Inc. (LNSR) has a return on equity (ROE) of -95.4%. Negative ROE indicates the company is unprofitable.

LENSAR, Inc. (LNSR) had negative free cash flow of $11.9M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.